Clene

Clene Financing Cash Flow

The Net Financing Cash Flow of Clene (CLNN) as of Nov 16, 2026 is 11.52 M USD. In the previous year, Net Financing Cash Flow was -1.53 M USD — a change of -853.30% (higher).

Financing Cash Flow

11.52 MUSD

YoY

-853.30%

Last updated:

Net Financing Cash Flow of Clene is 2025 11.52 M USD. Net Financing Cash Flow of Clene was 2024 -1.53 M USD. It decreases by -853.30% higher compared to the previous year.

The Clene Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
46.95 M USD
Jan 1, 2019
5.50 M USD
Jan 1, 2020
69.53 M USD
Jan 1, 2021
27.11 M USD
Jan 1, 2022
17.25 M USD
Jan 1, 2023
42.16 M USD
Jan 1, 2024
-1.53 M USD
Jan 1, 2025
11.52 M USD
The Clene Financing Cash Flow history
YEARFinancing Cash FlowYoY
11.52 MUSD-853.30%
-1.53 MUSD-103.63%
42.16 MUSD+144.44%
17.25 MUSD-36.38%
27.11 MUSD-61.01%
69.53 MUSD+1,163.57%
5.50 MUSD-88.28%
46.95 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Net Financing Cash Flow of Clene is 11.52 M USD in 2025.

Net Financing Cash Flow of Clene changed from -1.53 M USD to 11.52 M USD, representing a -853.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Clene since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene